間質性肺疾患におけるインターロイキン-17Cの役割:気管支拡張症および喘息の重複におけるインターロイキン-17Aの病原性および喘息の病態型スイッチングの促進に関するエビデンス
Yu-Wei Zhang1,2,3, Yu-Hua Wen3, Ling Yang3
1Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, China.
Nature communications
|December 26, 2025
まとめ
インターロイキン-17C(IL-17C)は、気管支拡張症-喘息の重複(BAO)においてIL-17Aを駆動し、好中球性喘息を促進します。IL-17Cを標的とすることは、BAO患者の新たな治療戦略を提供する可能性があります。
科学分野:
- 免疫学
- 呼吸器医学
- 病態生理学
背景:
- 気管支拡張症と喘息の重複(BAO)は管理上の課題をもたらす。
- BAOを駆動する特定の病態型は十分に理解されていない。
- インターロイキン-17(IL-17)経路の呼吸器疾患への関与がますます認識されている。
研究 の 目的:
- BAOの病態生理におけるIL-17Cの役割を調査する。
- BAO患者におけるIL-17C、IL-17A、およびグループ3自然リンパ球(ILC3)の関係を探る。
- 気管支拡張症の文脈における喘息の病態型スイッチングにIL-17Cがどのように影響するかを解明する。
主な方法:
- 気管支拡張症および併存喘息患者の募集。
- IL-17C、IL-17A、およびILC3レベルの末梢血サンプルの分析。
- 緑膿菌感染および卵白アルブミン誘発喘息を含むマウスモデルの開発と利用。
主要な成果:
- BAO患者におけるIL-17CとIL-17A/ILC3レベルの正の相関。
- IL-17CはマウスモデルにおいてIL-17受容体Eを介してILC3におけるIL-17A発現を増強する。
- Il17reの除去はマウスにおけるILC3応答を低下させ、IL-17A駆動型喘息の病態型スイッチングを軽減した。
- 緑膿菌感染による上皮バリア機能不全は、IL-17C産生の増加と相関していた。
結論:
- IL-17Cは、BAOにおけるIL-17Aの病原性を制御する上で重要な役割を果たしている。
- IL-17Cは、気管支拡張症における好中球性表現型への喘息の病態型スイッチングを促進する。
- IL-17Cは、BAO管理のための潜在的な治療標的として浮上している。
関連する概念動画
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K


